Inhibition of Sirt6 suppresses tumor growth by inducing G1/S phase arrest in renal cancer cells.
Inhibition of Sirt6 suppresses tumor growth by inducing G1/S phase arrest in renal cancer cells.
复制标题
抑制 Sirt6 可通过诱导肾癌细胞 G1/S 期停滞来抑制肿瘤生长。
DOI：
--
复制
发表时间：
2019
影响因子：
1.4
通讯作者：
Wei Jiang
中科院分区：
文献类型：
--
作者：
Yu Ding;Sisi Wu;Yuwei Huo;Xuemei Chen;Li Chai;Yan Wang;Xiangxiu Wang;Guonian Zhu;Wei Jiang
Sirt6是Sirtuin家族的重要成员，在细胞凋亡、衰老、DNA损伤修复、端粒稳态和完整性、能量代谢、葡萄糖稳态和基因调控等方面发挥关键作用。在最近的研究中，Sirt6在几种癌症中下调，并被预测为肿瘤抑制基因，但在其他癌症中作为肿瘤致癌基因。在这项研究中，我们探讨了Sirt6在人肾细胞癌（RCC）中的具体作用。我们发现Sirt6在肾肿瘤组织和细胞中表达上调。RCC中Sirt6沉默导致G1/S期阻滞，细胞凋亡增加，细胞活力降低，以及化疗敏感性增强。综上所述，这些发现表明Sirt6在人类RCC中起致癌基因的作用，它可能是RCC治疗的潜在靶点。
Sirt6 is a vital member of the Sirtuin family that plays a key role in cellular apoptosis, aging, DNA damage repair, telomere homeostasis and integrity, energy metabolism, glucose homeostasis, and gene regulation. In recent studies, Sirt6 is down-regulated in several cancers and predicted to be a tumor suppressor, but as a tumor oncogene in other cancers. In this study, we explored the specific role of Sirt6 in human renal cell carcinoma (RCC). We found that Sirt6 was up-expressed in renal tumor tissues and cells. Sirt6 silence in RCC led to G1/S phase arrest, a rise in apoptosis and a decrease in cell viability, as well as an enhancement of chemotherapeutic sensitivity. In conclusion, these findings suggest that Sirt6 acted as an oncogene in human RCC and it could be a potential target for RCC treatment.